Cibus, Inc. (CBUS)
NASDAQ: CBUS · Real-Time Price · USD
1.420
-0.070 (-4.70%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Company Description

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits.

The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients.

it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name.

The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Cibus, Inc.
Cibus logo
Country United States
Founded 2010
IPO Date Jul 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 118
CEO Peter Beetham

Contact Details

Address:
6455 Nancy Ridge Drive
San Diego, California 92121
United States
Phone 858 450 0008
Website cibus.com

Stock Details

Ticker Symbol CBUS
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001705843
CUSIP Number 17166A101
ISIN Number US17166A1016
Employer ID 27-1967997
SIC Code 2870

Key Executives

Name Position
Dr. Peter R. Beetham B.Sc., Ph.D. Co-Founder, Interim Chief Executive Officer, President, Chief Operating Officer and Director
Rory Balfour Riggs M.B.A. Co-Founder and Director
Cornelis Broos M.Sc. Chief Financial Officer
Dr. Gregory F. Gocal Ph.D. Co-Founder, Chief Scientific Officer and Executive Vice President
Jason Stokes Esq., J.D. Chief Administrative Officer, General Counsel and Corporate Secretary
Rosa Cheuk Kim J.D. Senior Vice President of Legal
Dr. Noel Sauer Ph.D. Senior Vice President of Research

Latest SEC Filings

Date Type Title
Apr 20, 2026 ARS Filing
Apr 20, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 20, 2026 DEF 14A Other definitive proxy statements
Apr 10, 2026 8-K Current Report
Mar 27, 2026 8-K Current Report
Mar 26, 2026 424B5 Filing
Mar 25, 2026 424B5 Filing
Mar 17, 2026 10-K Annual Report
Mar 17, 2026 8-K Current Report
Feb 5, 2026 SCHEDULE 13G/A Filing